Oct 27, 2026 07:00AM
Sep 8, 2026 04:05PM
Sep 8, 2026 04:05PM
Sep 2, 2026 07:05AM
Sep 1, 2026 07:15AM
Aug 31, 2026 01:05PM
Aug 28, 2026 08:30PM FDA approves Takeda's rusfertide for polycythemia vera treatment
Aug 28, 2026 08:30PM
Aug 18, 2026 04:05PM
Aug 5, 2026 04:05PM
Aug 4, 2026 04:05PM
Jul 16, 2026 04:05PM
Jul 1, 2026 04:05PM
Jun 16, 2026 04:00PM Protagonist Therapeutics Reports Granting of Inducement Awards
May 28, 2026 07:05AM
May 5, 2026 04:05PM
Apr 28, 2026 09:05AM
Apr 16, 2026 04:05PM
Mar 28, 2026 10:05AM
Mar 28, 2026 10:05AM
Mar 18, 2026 03:39PM Protagonist Therapeutics (PTGX) PT Raised to $104 at Clear Street
Mar 18, 2026 12:17PM
Mar 18, 2026 10:28AM
Mar 18, 2026 08:05AM
Mar 18, 2026 08:05AM
Mar 2, 2026 06:01AM
Mar 2, 2026 02:00AM
Feb 25, 2026 05:15PM CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Feb 25, 2026 04:05PM
Jan 30, 2026 06:47AM
Jan 5, 2026 07:03AM
Jan 5, 2026 07:00AM
Dec 12, 2025 04:54AM
Dec 8, 2025 02:54AM
Dec 6, 2025 09:30AM Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
Nov 6, 2025 04:05PM
Oct 7, 2025 11:00PM
Aug 7, 2025 04:18AM
Aug 6, 2025 04:05PM
Jun 1, 2025 08:00AM
Mar 3, 2025 01:28PM
Mar 3, 2025 06:46AM Protagonist Therapeutics (PTGX) and Takeda (TAK) Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
Mar 3, 2025 06:45AM
Feb 21, 2025 07:00AM
Jan 6, 2025 04:05PM
Nov 7, 2024 04:05PM
Apr 16, 2024 09:00AM
Jan 31, 2024 04:09PM
Jan 31, 2024 04:05PM Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
Apr 4, 2023 05:41PM

335,561 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All